Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -0,1x - -0,1x | -0,1x |
| Selected Fwd EBIT Multiple | -0,1x - -0,1x | -0,1x |
| Fair Value | $2,96 - $3,11 | $3,03 |
| Upside | 62,4% - 70,6% | 66,5% |
| Benchmarks | Ticker | Full Ticker |
| Dyadic International, Inc. | DYAI | NasdaqCM:DYAI |
| Cardiff Oncology, Inc. | CRDF | NasdaqCM:CRDF |
| Geron Corporation | GERN | NasdaqGS:GERN |
| Trevena, Inc. | TRVN | OTCPK:TRVN |
| Ainos, Inc. | AIMD | NasdaqCM:AIMD |
| X4 Pharmaceuticals, Inc. | XFOR | NasdaqCM:XFOR |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| DYAI | CRDF | GERN | TRVN | AIMD | XFOR | ||
| NasdaqCM:DYAI | NasdaqCM:CRDF | NasdaqGS:GERN | OTCPK:TRVN | NasdaqCM:AIMD | NasdaqCM:XFOR | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | 30.5% | -17.6% | 36.0% | 6.9% | -2.6% | 1.7% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -420.4% | -8004.2% | -23737.0% | -15325.1% | -11847.9% | -6415.6% | |
| Prior Fiscal Year | -282.6% | -9305.7% | -81832.9% | 13486.8% | -10580.1% | NA | |
| Latest Fiscal Year | -168.2% | -7123.1% | -225.6% | -1129.2% | -66772.2% | -5530.0% | |
| Latest Twelve Months | -161.9% | -8875.6% | -115.5% | -5880.0% | -13072.6% | -362.1% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 8.67x | 316.14x | 4.03x | 45.74x | 189.17x | 0.05x | |
| EV / LTM EBITDA | NA | -3.6x | -3.5x | -0.8x | -2.2x | 0.0x | |
| EV / LTM EBIT | -5.4x | -3.6x | -3.5x | -0.8x | -1.4x | 0.0x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -5.4x | -3.5x | -0.8x | ||||
| Historical EV / LTM EBIT | -1.0x | -0.5x | -0.4x | ||||
| Selected EV / LTM EBIT | -0.1x | -0.1x | -0.1x | ||||
| (x) LTM EBIT | (114) | (114) | (114) | ||||
| (=) Implied Enterprise Value | 9 | 10 | 10 | ||||
| (-) Non-shareholder Claims * | 9 | 9 | 9 | ||||
| (=) Equity Value | 18 | 19 | 19 | ||||
| (/) Shares Outstanding | 5.8 | 5.8 | 5.8 | ||||
| Implied Value Range | 3.12 | 3.20 | 3.29 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 3.12 | 3.20 | 3.29 | 1.82 | |||
| Upside / (Downside) | 71.4% | 76.0% | 80.5% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | DYAI | CRDF | GERN | TRVN | AIMD | XFOR | |
| Enterprise Value | 31 | 186 | 469 | 25 | 20 | 2 | |
| (+) Cash & Short Term Investments | 7 | 80 | 397 | 13 | 3 | 87 | |
| (+) Investments & Other | 0 | 0 | 59 | 0 | 0 | 0 | |
| (-) Debt | (5) | (1) | (122) | (38) | (12) | (78) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 33 | 264 | 803 | 1 | 11 | 11 | |
| (/) Shares Outstanding | 30.1 | 66.5 | 636.9 | 1.0 | 4.2 | 5.8 | |
| Implied Stock Price | 1.10 | 3.97 | 1.26 | 0.91 | 2.58 | 1.82 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1.10 | 3.97 | 1.26 | 0.91 | 2.58 | 1.82 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |